

## References

I-130

1. Rosenblad T, Rebetz J, Johansson M, et al. Eculizumab treatment for rescue of renal function in IgA nephropathy. *Pediatr Nephrol*. 2014;29(11):2225-2228.
2. Orandi BJ, Zachary AA, Dagher NN, et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. *Transplantation*. 2014;98(8):857-865.
3. Vivarelli M, Emma F. Treatment of C3 glomerulopathy with complement blockers. *Semin Thromb Hemost*. 2014;40(4):472-477.
4. Dezern AE, Dorr D, Brodsky RA. Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria. *Eur J Haematol*. 2013;90(1):16–24.
5. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. *Blood*. 2013;121(25):4985-4996.
6. Hillmen P, Muus P, Röth A, Elebute MO, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. *Br J Haematol*. 2013;162(1):62-73.
7. Varela JC, Brodsky RA. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition. *Expert Rev Clin Immunol*. 2013;9(11):1113-1124.
8. Howard JF Jr, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. *Muscle Nerve*. 2013;48(1):76-84.
9. Schrezenmeier H, Muus P, Socié G, Szer J, Urbano-Ispizua A, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. *Haematologica*. 2014;99(5):922–29.
10. Lee J, Jang J, Kim J, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. *Int J Hematol*. 2013;97(6):749-57.
11. American Society of Hematology (ASH). Compliment and hematology. January 17, 2011.
12. Yuan X, Gavriilaki E, Brodsky R, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. *Haematologica*. 2017;102:466-475.
13. Sasapu A, Cottler-Fox M, Motwani P. Acquired thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome successfully treated with eculizumab. *Baylor University Medical Center Proceedings*. 2017;30:182-183.
14. Tran D, Boucher A, Collette S, et al. Eculizumab for the Treatment of Severe Antibody-Mediated Rejection: A Case Report and Review of the Literature. *Case Reports in Transplantation*. 2016;1-4.
15. Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): a

phase 3, randomised, double-blind, placebo-controlled, multicentre study. *Lancet Neurol.* 2017;976–86.

16. MICROMEDEX®SOLUTIONS Compendia. 2017. ECULIZUMAB.
17. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. ECULIZUMAB.
18. MICROMEDEX®SOLUTIONS Compendia. 2018. Eculizumab.
19. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Eculizumab.
20. Howard Jr JF, Utsugisawa K, Benator M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. *Lancet Neurol.* 2017;16:976–86.
21. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America (Jaretzki A III, Barohn RJ, et al). Myasthenia Gravis. Recommendations for clinical research standards. *Neurology.* 2000;55:16-23.
22. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare.* 2016. Accessed October 11, 2017.
23. Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. *Blood.* 2011;6786-6793.
24. ASHP Guidelines on Home Infusion Pharmacy Services, 2013. Accessed October 11, 2017.
25. MCG™ Care Guidelines, 21st edition, 2017, Home Infusion Therapy, CMT: CMT-0009(SR).